The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Open accessAbstract
CRISPR RNA-guided nucleases (RGNs) are widely used genome-editing reagents, but methods to delineate their genome-wide, off-target cleavage activities have been lacking. Here we describe an approach for global detection of DNA double-stranded breaks (DSBs) introduced by RGNs and potentially other nucleases. This method, called genome-wide, unbiased identification of DSBs enabled by sequencing (GUIDE-seq), relies on capture of double-stranded oligodeoxynucleotides into DSBs. Application of GUIDE-seq to 13 RGNs in two human cell lines revealed wide variability in RGN off-target activities and unappreciated characteristics of off-target sequences. The majority of identified sites were not detected by existing computational methods or chromatin immunoprecipitation sequencing (ChIP-seq). GUIDE-seq also identified RGN-independent genomic breakpoint 'hotspots'. Finally, GUIDE-seq revealed that truncated guide RNAs exhibit substantially reduced RGN-induced, off-target DSBs. Our experiments define the most rigorous framework for genome-wide identification of RGN off-target effects to date and provide a method for evaluating the safety of these nucleases before clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target profiling of AsCas12a-crRNA+11 genome editing in HEK293/3272-26A>G cells18,42 showed very high specificity, as demonstrated by exclusive editing of the 3272-26A>G CFTR locus, while non-specific cleavages in the second allele, or any other genomic loci, could not be detected (Fig. 2c and Supplementary Fig. 4c).”
From Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing (2019) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“While cleavage at sites with perfect complementarity to the protospacer domain of the gRNA typically occurs with highest efficiency, cleavage at sites having one to several bases of mismatch with the gRNA can occur. These undesired cleavage events are called “off-target effects” (OTEs)10, and their existence should be minimized for therapeutic applications of genome editing technologies.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The GUIDE-seq procedure10 can be used to empirically identify real off-target sites in cells.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq can detect off-target sites with indel frequencies as low as 0.03% (Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“GUIDE-seq is more sensitive than the IDLV method because dsODNs integrate more efficiently and precisely into DSBs, while the integration events of IDLV is low in number and can distribute as far as 500bp away from the actual DSB sites (Tsai et al., 2015; Cromer et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“However, other publications observed a much lower validation rate (Cencic et al., 2014; Duan et al., 2014; Tsai et al., 2015).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“These studies indicated that Cas9 could associate with genomic loci without exerting its nuclease function, deposing a major caveat in Cas9 ChIP-Seq-based off-target detection assay.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, compared to cell-based methods such as GUIDE-seq (see next section) (Tsai et al., 2015), Extru-seq exhibited much lower false negative rate (2.3% versus 29%) (Kwon et al., 2023).”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Tsai et al., 2015
In the citing paper
“Using the standard Guide-seq protocol, we detected only the Fah target site and one off-target site (defined as Guide-seq off-target site 1, or GOT1) (Supplementary Data Set 1).”
From Adenine base editing in an adult mouse model of tyrosinaemia (2019) · cites this paper as [23]
In the citing paper
“However, silicon methods can only identify part of the off-target cleavage.48”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [48]
In the citing paper
“The major barrier of clinical use of CRISPR/Cas9 is its off-target effects [81,82,83].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Fast and accurate long-read alignment with Burrows-Wheeler transform.
Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citationCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,009
Polstein, L. R., Pérez‐Piñera, P., Koçak, D. D., Vockley, C. M., Bledsoe, P. J., Song, L., Safi, A., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.179044.114 · Cited by 132
Biomedical applications of mRNA nanomedicine
Xiong, Q., Lee, G. Y., Ding, J., Li, W., & Shi, J. (2018) · Nano Research · doi:10.1007/s12274-018-2146-1 · Cited by 125
RNA Interference (RNAi) Screening in Drosophila
Heigwer, F., Port, F., & Boutros, M. (2018) · Genetics · doi:10.1534/genetics.117.300077 · Cited by 125
The NIH Somatic Cell Genome Editing program
Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., Murray, S. A., Tsai, S. Q., Wilson, R. C., Anderson, D. G., et al. (2021) · Nature · doi:10.1038/s41586-021-03191-1 · Cited by 127
Self-citationA new age of precision gene therapy
Schambach, A., Buchholz, C. J., Torres-Ruiz, R., Cichutek, K., Morgan, M. A., Trapani, I., & Büning, H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01952-9 · Cited by 135
Characterization of noncoding regulatory DNA in the human genome
Elkon, R., & Agami, R. (2017) · Nature Biotechnology · doi:10.1038/nbt.3863 · Cited by 132
The Current State and Future of CRISPR-Cas9 gRNA Design Tools
Wilson, L. O. W., O’Brien, A. R., & Bauer, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00749 · Cited by 124
NmeCas9 is an intrinsically high-fidelity genome-editing platform
Amrani, N., Gao, X. D., Liu, P., Edraki, A., Mir, A., Ibraheim, R., Gupta, A., Sasaki, K. E., Wu, T., Donohoue, P. D., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1591-1 · Cited by 128
Iannelli, F., Galbiati, A., Capozzo, I., Nguyen, Q. H., Magnuson, B., Michelini, F., D’Alessandro, G., Cabrini, M., Roncador, M., Francia, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15656 · Cited by 124
Romero, Z. G., Lomova, A., Said, S., Hoyt-Miggelbrink, A. M., Kuo, C. Y., Campo-Fernández, B., Hoban, M. D., Masiuk, K. E., Clark, D. N., Long, J. D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.014 · Cited by 123
Lee, C. M., Cradick, T. J., Fine, E. J., & Bao, G. (2016) · Molecular Therapy · doi:10.1038/mt.2016.1 · Cited by 123
Development of hRad51–Cas9 nickase fusions that mediate HDR without double-stranded breaks
Rees, H. A., Yeh, W.-H., & Liu, D. R. (2019) · Nature Communications · doi:10.1038/s41467-019-09983-4 · Cited by 129
Human genetic diversity alters off-target outcomes of therapeutic gene editing
Cancellieri, S., Zeng, J., Lin, L. Y., Tognon, M., Nguyen, M. A., Lin, J., Bombieri, N., Maitland, S. A., Ciuculescu, M.-F., Katta, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01257-y · Cited by 125
Self-citationFrom Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing
Hotta, A., & Yamanaka, S. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054926 · Cited by 124
Evaluation and Reduction of CRISPR Off-Target Cleavage Events
Vakulskas, C. A., & Behlke, M. A. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0790 · Cited by 130
Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair
Schubert, M. S., Thommandru, B., Woodley, J., Turk, R., Yan, S., Kurgan, G., McNeill, M., & Rettig, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-98965-y · Cited by 131
Therapeutic gene editing: delivery and regulatory perspectives
Shim, G., Kim, D., Park, G. T., Jin, H., Suh, S., & Oh, Y. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.2 · Cited by 125
CRISPR/Cas9-mediated noncoding RNA editing in human cancers
Yang, J., Meng, X., Pan, J., Jiang, N., Zhou, C., Wu, Z., & Gong, Z. (2017) · RNA Biology · doi:10.1080/15476286.2017.1391443 · Cited by 122
Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol
Wang, L., Smith, J., Breton, C. A., Clark, P., Zhang, J., Lei, Y., Che, Y., Lape, J., Bell, P. L., Calcedo, R., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4182 · Cited by 119
Advanced CRISPR/Cas-based genome editing tools for microbial biofuels production: A review
Shanmugam, S., Ngo, H. H., & Wu, Y. (2019) · Renewable Energy · doi:10.1016/j.renene.2019.10.107 · Cited by 120
Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski‐Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U. C., Grundhoff, A. T., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3467 · Cited by 125
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
Huang, C., Lee, K.-C., & Doudna, J. A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.006 · Cited by 119
VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
Montagna, C., Petris, G., Casini, A., Maule, G., Franceschini, G. M., Zanella, I., Conti, L., Arnoldi, F., Burrone, O. R., Zentilin, L., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.05.010 · Cited by 117
Precision Control of CRISPR-Cas9 Using Small Molecules and Light
Gangopadhyay, S. A., Cox, K. J., Manna, D., Lim, D., Maji, B., Zhou, Q., & Choudhary, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01202 · Cited by 119
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Casirati, G., Cosentino, A., Mucci, A., Mahmoud, M. S., Zabala, I. U., Zeng, J., Ficarro, S. B., Klatt, D., Brendel, C., Rambaldi, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06496-5 · Cited by 124
CRISPR/Cas9-mediated genome engineering of CHO cell factories: application and perspectives
Lee, J. S., Grav, L. M., Lewis, N. E., & Faustrup Kildegaard, H. (2015) · Biotechnology Journal · doi:10.1002/biot.201500082 · Cited by 117
Genome Editing: A New Approach to Human Therapeutics
Porteus, M. H. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124454 · Cited by 118
Sherkatghanad, Z., Abdar, M., Charlier, J., & Makarenkov, V. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad131 · Cited by 123
Precise and efficient scarless genome editing in stem cells using CORRECT
Kwart, D., Paquet, D., Teo, S., & Tessier‐Lavigne, M. (2017) · Nature Protocols · doi:10.1038/nprot.2016.171 · Cited by 119
Huang, T. P., Heins, Z., Miller, S. M., Wong, B. G., Balivada, P. A., Wang, T., Khalil, A. S., & Liu, D. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01410-2 · Cited by 120
DNA-binding-domain fusions enhance the targeting range and precision of Cas9
Bolukbasi, M. F., Gupta, A., Oikemus, S., Derr, A. G., Garber, M. G., Brodsky, M. H., Zhu, L. J., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3624 · Cited by 117
Harnessing type I CRISPR–Cas systems for genome engineering in human cells
Cameron, P., Coons, M. M., Klompe, S. E., Lied, A. M., Smith, S. C., Vidal, B., Donohoue, P. D., Rotstein, T., Kohrs, B., Nyer, D. B., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0310-0 · Cited by 114
Precision cancer mouse models through genome editing with CRISPR-Cas9
Mou, H., Kennedy, Z., Anderson, D. G., Yin, H., & Xue, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0178-7 · Cited by 116
Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders
Wojtal, D., Kemaladewi, D. U., Malam, Z., Abdullah, S., Wong, T. W. Y., Hyatt, E., Baghestani, Z., Pereira, S., Stavropoulos, J., Mouly, V., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.012 · Cited by 121
Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications
Li, Y., Glass, Z., Huang, M., Chen, Z., & Xu, Q. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119711 · Cited by 118
CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells
Goodwin, M., Lee, E., Lakshmanan, U., Shipp, S., Froessl, L. J., Barzaghi, F., Passerini, L., Narula, M., Sheikali, A., Lee, C. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz0571 · Cited by 113
Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing
Valentine, C. C., Young, R. R., Fielden, M. R., Kulkarni, R. M., Williams, L. N., Li, T., Minocherhomji, S., & Salk, J. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013724117 · Cited by 113
CRISPR guide RNA design for research applications
Mohr, S. E., Hu, Y., Ewen‐Campen, B., Housden, B. E., Viswanatha, R., & Perrimon, N. (2016) · FEBS Journal · doi:10.1111/febs.13777 · Cited by 112
Lessard, S., Francioli, L. C., Alföldi, J., Tardif, J., Ellinor, P. T., MacArthur, D. G., Lettre, G., Orkin, S. H., & Canver, M. C. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714640114 · Cited by 115
Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing
Mir, A., Alterman, J. F., Hassler, M. R., Debacker, A. J., Hudgens, E. D., Echeverria, D., Brodsky, M. H., Khvorova, A., Watts, J. K., & Sontheimer, E. J. (2018) · Nature Communications · doi:10.1038/s41467-018-05073-z · Cited by 112
Strategies to Increase On-Target and Reduce Off-Target Effects of the CRISPR/Cas9 System in Plants
Hajiahmadi, Z., Movahedi, A., Wei, H., Li, D., Orooji, Y., Ruan, H., & Zhuge, Q. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153719 · Cited by 112
Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase
Witte, I. P., Lampe, G. D., Eitzinger, S., Miller, S. M., Berríos, K. N., McElroy, A. N., King, R. T., Stringham, O. G., Gelsinger, D. R., Vo, P. L. H., et al. (2025) · Science · doi:10.1126/science.adt5199 · Cited by 121
Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery
Bolukbasi, M. F., Gupta, A., & Wolfe, S. A. (2015) · Nature Methods · doi:10.1038/nmeth.3684 · Cited by 112
Sriramachandran, A. M., Petrosino, G., Méndez-Lago, M., Schäfer, A. J., Batista-Nascimento, L. S., Zilio, N., & Ulrich, H. D. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.03.027 · Cited by 114
Farasat, I., & Salis, H. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004724 · Cited by 114
Humbert, O., Radtke, S., Samuelson, C., Carrillo, R. R., Perez, A. M., Reddy, S. S., Lux, C. T., Pattabhi, S., Schefter, L. E., Nègre, O., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw3768 · Cited by 112
CRISPR/Cas9 gene editing for curing sickle cell disease
Park, S. H., & Bao, G. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103060 · Cited by 118
Genome editing: the road of CRISPR/Cas9 from bench to clinic
Eid, A., & Mahfouz, M. M. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.111 · Cited by 111
Lonowski, L. A., Narimatsu, Y., Riaz, A., Delay, C. M., Yang, Z., Niola, F., Duda, K., Ober, E. A., Clausen, H., Wandall, H. H., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2016.165 · Cited by 111
Gene drives to fight malaria: current state and future directions
Hammond, A., & Galizi, R. (2017) · Pathogens and Global Health · doi:10.1080/20477724.2018.1438880 · Cited by 114
Global detection of DNA repair outcomes induced by CRISPR–Cas9
Liu, M., Zhang, W., Xin, C., Yin, J., Shang, Y., Chen, A., Li, J., Meng, F., & Hu, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab686 · Cited by 117
Engineering the next generation of CAR-NK immunotherapies
Biederstädt, A., & Rezvani, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03209-4 · Cited by 114
DIG-Seq: A genome-wide CRISPR off-target profiling method using chromatin DNA
Kim, D., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.236620.118 · Cited by 108
How specific is CRISPR/Cas9 really?
O’Geen, H., Yu, A. S., & Segal, D. J. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.10.001 · Cited by 108
Zebrafish as a model for kidney function and disease
Outtandy, P., Russell, C., Kleta, R., & Böckenhauer, D. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3921-7 · Cited by 116
Hybridization Kinetics Explains CRISPR-Cas Off-Targeting Rules
Klein, M., Eslami-Mossallam, B., Arroyo, D. G., & Depken, M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.045 · Cited by 113
Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity
Tan, Y., Chu, A. H. Y., Bao, S., Hoang, D. A., Kebede, F. T., Xiong, W., Ji, M., Shi, J., & Zheng, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906843116 · Cited by 110
Self-citationOff-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Kalter, N., Fuster‐García, C., Silva, A., Ronco-Díaz, V., Roncelli, S., Turchiano, G., Gorodkin, J., Cathomen, T., Benabdellah, K., Lee, C. M., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102636 · Cited by 121
CRISPR/Cas9-Enabled Multiplex Genome Editing and Its Application
Minkenberg, B., Wheatley, M. S., & Yang, Y. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.05.003 · Cited by 107
Tools for experimental and computational analyses of off-target editing by programmable nucleases
Bao, X. R., Pan, Y., Lee, C. M., Davis, T. H., & Bao, G. (2021) · Nature Protocols · doi:10.1038/s41596-020-00431-y · Cited by 106
Chromatin regulation at the frontier of synthetic biology
Keung, A. J., Joung, J. K., Khalil, A. S., & Collins, J. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3900 · Cited by 109
Self-citationdCas9: A Versatile Tool for Epigenome Editing
Brocken, D. J. W., Tark‐Dame, M., & Dame, R. T. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.015 · Cited by 113
Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system
Takayama, K., Igai, K., Hagihara, Y., Hashimoto, R., Hanawa, M., Sakuma, T., Tachibana, M., Sakurai, F., Yamamoto, T., & Mizuguchi, H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx130 · Cited by 106
CRISPR/Cas9 editing of carotenoid genes in tomato
D’Ambrosio, C., Stigliani, A. L., & Giorio, G. (2018) · Transgenic Research · doi:10.1007/s11248-018-0079-9 · Cited by 107
Cas9 interrogates DNA in discrete steps modulated by mismatches and supercoiling
Ivanov, I. E., Wright, A. V., Cofsky, J. C., Aris, K., Doudna, J. A., & Bryant, Z. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913445117 · Cited by 109
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03765-1 · Cited by 114
Modeling Disease In Vivo With CRISPR/Cas9
Dow, L. E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.006 · Cited by 111
CRISPR/Cas9 for Human Genome Engineering and Disease Research
Xiong, X., Chen, M., Lim, W. A., Zhao, D., & Qi, L. S. (2016) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083115-022258 · Cited by 111
Decoding non-random mutational signatures at Cas9 targeted sites
Taheri‐Ghahfarokhi, A., Taylor, B., Nitsch, R., Lundin, A., Cavallo, A.-L., Madeyski-Bengtson, K., Karlsson, F. H., Clausen, M., Hicks, R., Mayr, L. M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky653 · Cited by 111
Template plasmid integration in germline genome-edited cattle
Norris, A. L., Lee, S. S., Greenlees, K. J., Tadesse, D. A., Miller, M. F., & Lombardi, H. A. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0394-6 · Cited by 105
Enabling functional genomics with genome engineeringPreprint
Hilton, I. B., & Gersbach, C. A. (2015) · Genome Research · doi:10.1101/gr.190124.115 · Cited by 106
Abdelrahman, M., Al-Sadi, A. M., Pour-Aboughadareh, A., Burritt, D. J., & Tran, L.-S. P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.012 · Cited by 103
CRISPR engineering in organoids for gene repair and disease modelling
Geurts, M. H., & Clevers, H. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00013-5 · Cited by 103
Optimizing genome editing strategy by primer-extension-mediated sequencing
Yin, J., Liu, M., Liu, Y., Wu, J., Gan, T., Zhang, W., Li, Y., Zhou, Y., & Hu, J. (2019) · Cell Discovery · doi:10.1038/s41421-019-0088-8 · Cited by 108
Young, J. K., Zastrow‐Hayes, G., Deschamps, S., Svitashev, S. K., Zaremba, M., Acharya, A., Paulraj, S., Peterson-Burch, B. D., Schwartz, C. S., Djukanovic, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43141-6 · Cited by 108
Resources for the design of CRISPR gene editing experiments
Graham, D. B., & Root, D. E. (2015) · Genome biology · doi:10.1186/s13059-015-0823-x · Cited by 108
Minkenberg, B., Zhang, J., Xie, K., & Yang, Y. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.13025 · Cited by 102
CRISPR/Cas9 gRNA activity depends on free energy changes and on the target PAM context
Corsi, G. I., Qu, K., Alkan, F., Pan, X., Luo, Y., & Gorodkin, J. (2022) · Nature Communications · doi:10.1038/s41467-022-30515-0 · Cited by 104
Lin, J., Zhang, Z., Zhang, S., Chen, J., & Wong, K. (2020) · Advanced Science · doi:10.1002/advs.201903562 · Cited by 101
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Ren, J., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0410-x · Cited by 103
Genome Editing Technologies: Defining a Path to Clinic
Corrigan‐Curay, J., O’Reilly, M., Kohn, D. B., Cannon, P. M., Bao, G., Bushman, F. D., Carroll, D., Cathomen, T., Joung, J. K., Roth, D. B., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.54 · Cited by 101
Self-citationAn overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools
Wang, J., Zhang, X., Cheng, L., & Luo, Y. (2019) · RNA Biology · doi:10.1080/15476286.2019.1669406 · Cited by 106
An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity
Wu, T., Liu, C., Zou, S., Lyu, R., Yang, B., Yan, H., Zhao, M., & Tang, W. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01380-9 · Cited by 104
Acharya, S., Mishra, A., Paul, D., Ansari, A. H., Azhar, M., Kumar, M., Rauthan, R., Sharma, N., Aich, M., Sinha, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818461116 · Cited by 102
Liu, M., Gong, S., Yu, H., Jung, K., Johnson, K. A., & Taylor, D. W. (2020) · Nature Communications · doi:10.1038/s41467-020-17411-1 · Cited by 104
Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics
Rose, J. C., Stephany, J. J., Valente, W. J., Trevillian, B. M., Dang, H. V., Bielas, J. H., Maly, D. J., & Fowler, D. M. (2017) · Nature Methods · doi:10.1038/nmeth.4368 · Cited by 101
Model-based understanding of single-cell CRISPR screening
Duan, B., Zhou, C., Zhu, C., Yu, Y., Li, G., Zhang, S., Zhang, C., Ye, X., Ma, H., Qu, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10216-x · Cited by 98
CRISPR/Cas System and Factors Affecting Its Precision and Efficiency
Javaid, N., & Choi, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761709 · Cited by 106
Engineered CRISPR prime editors with compact, untethered reverse transcriptases
Grünewald, J., Miller, B. R., Szalay, R. N., Cabeceiras, P. K., Woodilla, C. J., Holtz, E. J. B., Petri, K., & Joung, J. K. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01473-1 · Cited by 103
Self-citationHit and go CAS9 delivered through a lentiviral based self-limiting circuit
Petris, G., Casini, A., Montagna, C., Lorenzin, F., Prandi, D., Romanel, A., Zasso, J., Conti, L., Demichelis, F., & Cereseto, A. (2017) · Nature Communications · doi:10.1038/ncomms15334 · Cited by 98
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 100
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 109
Dastidar, S., Ardui, S., Singh, K., Majumdar, D., Nair, N., Fu, Y., Reyon, D., Samara-Kuko, E., Gerli, M., Klein, A. F., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky548 · Cited by 104
Self-citationKimberland, M. L., Hou, W., Alfonso-Pecchio, A. R., Wilson, S. P., Rao, Y., Zhang, S., & Lu, Q. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.08.007 · Cited by 99
Tadić, V., Josipović, G., Zoldoš, V., & Vojta, A. (2019) · Methods · doi:10.1016/j.ymeth.2019.05.003 · Cited by 99
Epigenome engineering: new technologies for precision medicine
Sgro, A., & Blancafort, P. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1000 · Cited by 96
Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo
Zekonyte, U., Bacman, S. R., Smith, J., Shoop, W. K., Pereira, C. V., Tomberlin, G., Stewart, J. B., Jantz, D., & Moraes, C. T. (2021) · Nature Communications · doi:10.1038/s41467-021-23561-7 · Cited by 96
Defining CRISPR–Cas9 genome-wide nuclease activities with CIRCLE-seq
Lazzarotto, C. R., Nguyen, N. T., Tang, X., Malagon-Lopez, J., Guo, J. A., Aryee, M. J., Joung, J. K., & Tsai, S. Q. (2018) · Nature Protocols · doi:10.1038/s41596-018-0055-0 · Cited by 98
Self-citationGuide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems
Filippova, J. A., Matveeva, A. M., Zhuravlev, E. S., & Stepanov, G. A. (2019) · Biochimie · doi:10.1016/j.biochi.2019.09.003 · Cited by 98
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., Sturgeon, M. L., Kurgan, G., Amini, L., Stein, M., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.018 · Cited by 103
Metadata
- Authors
- Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., Aryee, M. J., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Tsai, Shengdar Q
- Joung, J Keith
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2014-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 187-197
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4320685
- OpenAlex
- W2003797386
- Cited by
- 2,268
- References
- 39
- Citations by year
- 2026: 189 · 2025: 211 · 2024: 196 · 2023: 191 · 2022: 208 · 2021: 211 · 2020: 231 · 2019: 186 · 2018: 187 · 2017: 177 · 2016: 172 · 2015: 105 · 2014: 1
- FWCI
- 62.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM088040, F32GM105189)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR063070)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- GUIDE-seq, CRISPR-Cas nucleases, off-target cleavage, DNA double-strand breaks, genome-wide characterization, genome editing safety
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Cell Line, Humans, Oligodeoxyribonucleotides, Genome, Human, RNA Editing, DNA Breaks, Double-Stranded, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
